BGLC

Business Context and Reporting Period

Company: BioNexus Gene Lab Corp. (BGLC)
Filing Type: Form 10-Q (Unaudited)
Period Ended: June 30, 2025
Business Overview: BGLC operates through three primary segments: genomic screening services (MRNA Scientific), trading of industrial chemicals (Chemrex), and investment holding. The company is a smaller reporting company and an emerging growth company listed on Nasdaq. In April 2025, the company effected a 1-for-10 reverse stock split to regain Nasdaq compliance.

Key Financial Metrics (Six Months Ended June 30, 2025)

Material Changes vs. Prior Comparable Period

• Revenue: Increased 0.9% year-over-year (YoY) to $4.40 million. The industrial chemicals segment (Chemrex) drove growth with a 1.0% increase, while the genomic screening segment (MRNA Scientific) declined 24.6% due to equipment unavailability and fewer referrals.
• Profitability: The company swung from a net profit of $95,347 in the prior year to a net loss of $1.24 million. This was primarily driven by a 59.5% increase in operating expenses and a 67.7% decrease in "Other Income."
• Operating Expenses: Rose to $2.24 million from $1.41 million. Sales and marketing expenses surged 295.8% to $1.15 million, largely due to increased officer/director remuneration and new business development contracts at the Chemrex subsidiary.
• Other Income: Dropped significantly to $300,881 from $931,952. The decline was attributed to lower bank interest earnings, reduced fair value gains on equity investments, and a normalization of the reversal of expected credit losses (which was $584k in the prior period vs. $95k in the current period).
• Cash Flow: Net cash used in operating activities increased to $1.56 million from $709k in the prior period, reflecting the operational losses and working capital changes.

Guidance, Outlook, and Strategic Initiatives

• Chemrex CDMO Transition: The Board approved a strategic repositioning of Chemrex from industrial chemical trading to a biotechnology-focused Contract Development and Manufacturing Organization (CDMO). Up to MYR 10 million is authorized for facility upgrades and cleanroom infrastructure. This transition is expected to wind down chemical trading operations over time.
• Fidelion Diagnostics Partnership: In July 2025 (subsequent event), BGLC entered a non-binding term sheet with Fidelion Diagnostics for a cross-equity investment and exclusive commercialization rights for the VitaGuard™ MRD platform in Southeast Asia. Regulatory submissions are planned for 2026.
• Ethereum Treasury Strategy: Approved in March 2025, the company intends to hold Ethereum as a strategic treasury asset to enhance capital efficiency. As of June 30, 2025, no digital assets were held as management reviewed allocation strategies.
• Nasdaq Compliance: The company successfully regained compliance with Nasdaq listing standards in April 2025 following the reverse stock split.
• Internal Controls: Management identified a significant deficiency in internal controls at the Chemrex subsidiary regarding documentation and approval authority. A remediation plan is underway, including revised delegation of authority policies and enhanced oversight.

Investor Verification Checklist

• Going Concern Status: Verify management's assessment that liquidity is sufficient for the next 12 months despite the $1.24M net loss and negative operating cash flow.
• Chemrex Transition Risks: Assess the execution risk and timeline for the CDMO pivot, including the potential for revenue shortfalls during the wind-down of chemical trading.
• Internal Control Remediation: Monitor the progress of the remediation plan for Chemrex's internal control deficiencies to ensure they do not escalate to a material weakness.
• Fidelion Deal Closure: Confirm the execution of definitive agreements for the Fidelion Diagnostics partnership, as the current term sheet is non-binding.
• Digital Asset Volatility: Evaluate the impact of the Ethereum treasury strategy on future earnings volatility, given the fair value accounting treatment under US GAAP.